This Slide: #99 of 100 |
Slide #99. OPKO Health, Inc. — PROLOR Biotech, Inc.
Acquirer:
OPKO Health, Inc. (OPK)
Acquiree:
PROLOR Biotech, Inc. (PBTH)
Details:
OPKO Health, Inc. (NYSE: OPK) and PROLOR Biotech, Inc. (NYSE MKT: PBTH) today announced that the companies have signed a definitive merger agreement under which OPKO will acquire PROLOR, a biopharmaceutical company focused on developing and commercializing longer-acting proprietary versions of already approved therapeutic proteins, in an all-stock transaction. Under the terms of the agreement, which has been approved by the boards of directors of both companies, holders of PROLOR common stock will receive 0.9951 shares of OPKO common stock for each share of PROLOR common stock. Based on a price of $7.03 per share of OPKO common stock, the transaction is valued at approximately $480 million, or $7.00 per share of PROLOR common stock. The companies expect the transaction to be completed during the second half of 2013. Closing of the transaction is subject to certain conditions including, the approval of OPKO's and PROLOR's stockholders and other customary closing conditions.
Opko Health is a healthcare company. Co.'s reportable segments are: diagnostics, which consists of the clinical laboratory operations of its subsidiary, BioReference Laboratories, Inc. (BioReference), as well as its point-of-care operations; and pharmaceutical, which consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Through BioReference, Co. provides laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health and correctional healthcare.
OPK SEC Filing Email Alerts Service
Open the OPK Page at The Online Investor »
Opko Health is a healthcare company. Co.'s reportable segments are: diagnostics, which consists of the clinical laboratory operations of its subsidiary, BioReference Laboratories, Inc. (BioReference), as well as its point-of-care operations; and pharmaceutical, which consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Through BioReference, Co. provides laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health and correctional healthcare.
OPK SEC Filing Email Alerts Service
Open the PBTH Page at The Online Investor »
|
|
Free Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |